Biovica and Pelago Bioscience to collaborate on common platform for cancer drugs

7 September 2015

Biotech firms Pelago Bioscience and Biovica have agreed to work together to provide a common platform for developing new oncology drugs and treatments.

Swedish drug discovery company Pelago Bioscience’s cellular thermal shift assay (CETSA) technology helps provide physiologically relevant target engagement data. Biovica has developed DiviTum, a highly sensitive assay for measuring cell proliferation rate and prediction & monitoring efficacy of cell cycle regulating oncology drugs.

The common platform offers the opportunity to obtain crucial data earlier in the development of new therapies in the oncology field.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK